Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVT32-DRL_PB vs Keytruda in Adjuvant Melanoma
NCT07475572Phase 1Recruiting
- Sponsor
- Alvotech
- Start
- Aug 2026
- Primary completion
- Oct 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of pembrolizumab in melanoma (2 arms), sponsored by Alvotech. Primary endpoint: Pharmacokinetic similarity. Started Aug 2026; status: recruiting.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT07475572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07475572.